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a b s t r a c t
The use of extracorporeal membrane oxygenation (ECMO) for reversible pulmonary failure in critically ill
patients has increased over the last few decades. Nosocomial infections are a major complication of
ECMO and fungi have been found to be a common cause. Herein, we describe a case of invasive
pulmonary aspergillosis following ECMO, which was successfully treated with combination antifungal
therapy and interferon-gamma.
& 2014 The Authors. International Society for Human and Animal Mycology. Published by Elsevier B.V.
1. Introduction
The use of extracorporeal membrane oxygenation (ECMO) for
intensive care patients with severe cardiac or reversible pulmonary
failure has become more common over the last 30 years [1]. Complica-
tions resulting from ECMO further increase the mortality in this group
of patients, which is already high due to severity of underlying illness
[2]. After haemorrhage, infection is the secondmost common complica-
tion of ECMO, with reports of up to 45% of patients being affected [2,3].
Fungi such as Candida have been found to be a common cause of
infection in this group [4]. We describe a case where ECMO was
employed as a part of the management of severe community acquired
pneumonia (CAP) and the patient developed an invasive pulmonary
infection with Aspergillus fumigatus. This is the ﬁrst case to describe
successful treatment with combination antifungal therapy and
interferon-gamma. This case report also highlights the difﬁculty in
diagnosing invasive pulmonary aspergillosis (IPA), the importance of
monitoring voriconazole levels in the blood and of careful consideration
of antifungal drug interactions with other medication.
2. Case
A 48 year-old male presented with a 7-day history of cough,
shortness of breath and diarrhoea. His past medical history included
hypertension, chronic obstructive pulmonary disease (COPD) and
diet-controlled diabetes. Furthermore, he had worked as a welder
and was an ex-smoker. He was initially treated with amoxicillin and
steroids by his general practitioner but after 4 days his symptoms
worsened which led to hospital admission (day 0). He presented
with severe sepsis. Blood tests showed an increase in the markers of
infection (C-reactive protein and total white cell count were 279mg/L
and 21.9109/L respectively) and he had a base excess of 19.3. A
chest radiograph revealed right-sided consolidation. A diagnosis of
severe CAP was made and a course of intravenous amoxicillin-
clavulanate and clarithromycin was started. Unfortunately, he rapidly
developed multi-organ failure including type II respiratory failure
and further deteriorated resulting in a peri-arrest situation. He was
therefore intubated and transferred to the intensive care unit (ICU)
where he received sustained low-efﬁciency dialysis (SLED). A com-
puted tomography (CT) scan of his chest showed dense consolidation
throughout his right lung, with cavitations in the right upper lobe
(day þ1). A bronchoalveolar lavage (BAL) grew Staphylococcus
aureus, Streptococcus agalactiae, Streptococcus pneumoniae, and Hae-
mophilus inﬂuenza. His antibiotic therapy was changed to a combina-
tion of piperacillin–tazobactam, linezolid and clindamycin. He was
given two doses of intravenous immunoglobulin for suspected
Panton Valentine Leukocidin S. aureus (later found to be negative).
Other tests including blood cultures, respiratory viral PCR, culture
and PCR for Mycobacterium tuberculosis on BAL samples, culture of
CT-guided aspirate from lungs, atypical pneumonia serology screen,
stool culture and Legionella antibody and urinary antigen were all
negative. His condition worsened despite high frequency oscillatory
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/mmcr
Medical Mycology Case Reports
http://dx.doi.org/10.1016/j.mmcr.2014.01.003
2211-7539 & 2014 The Authors. International Society for Human and Animal Mycology. Published by Elsevier B.V.
n Corresponding author. Tel.: þ44 1382 660 111.
E-mail address: b.parcell@nhs.net (B.J. Parcell).
Medical Mycology Case Reports 4 (2014) 12–15
Open access under CC BY-NC-ND license.
Open access under CC BY-NC-ND license.
ventilation and therefore he was referred for consideration of, and
ultimately transferred for, ECMO at another tertiary centre (day þ4).
On day þ22, he was transferred back to our ICU after his condition
improved, but he remained critical. He had persistent pyrexia despite
treatment with linezolid and ciproﬂoxacin, with ﬂuconazole prophy-
laxis. A repeat CT scan of his chest revealed a large abscess in the
right lung (Fig. 1). A CT scan of the head showed 1.5 cm lesions in the
thalamus, basal ganglia and frontal lobe, which were thought to be
either fungal infection or haemorrhage secondary to ECMO. A.
fumigatus was grown from BAL and an endotracheal aspirate (ETA)
and he was started on amphotericin B (amBisome) increasing to
5 mg/kg and other antibiotics were stopped (day þ24).
A repeat BAL grew Serratia marcescens and A. fumigatus so he
was restarted on piperacillin–tazobactam (day þ31). A further ETA
grew S. aureus therefore ﬂucloxacillin, clindamycin, and rifampicin
were added. Repeat BAL grew more S. aureus and A. fumigates (day
þ34). The patient remained pyrexial and unable to be weaned
from ventilatory support. On day þ37, a chest drain was inserted
into the intra-pulmonary abscess under CT guidance. Cultures
grew profuse A. fumigatus sensitive to posaconazole, itraconazole,
voriconazole, amphotericin, and caspofungin. Voriconazole was
added to amBisome (day þ39) after a 2-week course of the latter
due to the well recognised penetration of this agent into brain
tissue. His liver function deteriorated, possibly due to an interac-
tion between rifampicin and voriconazole. Moreover, concomitant
rifampicin and voriconazole are contra-indicated as the former is
known to reduce the exposure of voriconazole by more than 90%
by inducing cytochrome P450 so rifampicin was stopped. A repeat
ETA aspirate grew Klebsiella oxytoca and Enterobacter cloacae (day
þ58). Gentamicin was added and he had a further course of
piperacillin–tazobactam. Aspergillus PCR on blood was negative
but this does not preclude a diagnosis of invasive aspergillosis
(day þ60). Trans-oesophageal echocardiography was performed
due to ongoing pyrexia and it ruled out endocarditis. Toxoplasma
serology and HIV testing were carried out and both were negative.
The patient was found to be anaemic, lymphopaenic, and throm-
bocythaemic (day þ72). Investigations for immune compromise
were carried out, particularly as the patient had been well prior to
his admission, multiple organisms had grown on culture and
disease had remained severe despite appropriate antifungals and
antibiotics. A bone marrow aspirate showed no changes attribu-
table to lymphoma however plasma B cells were abnormally low.
His IgG was 22.20 g/L, which was appropriately elevated and
compatible with infection. IgA was 6.73 g/L (moderately elevated)
and IgM 0.80 g/L, which was normal. Lymphocyte subsets were
normal apart from a low CD 19 (B cell) count of 15106/L. A CT
scan did not show changes suggestive of lymphoma. These
investigations suggested functional immune impairment and the
patient was not responding to treatment. After discussion with
immunologists and a thorough literature search a course of
interferon-gamma was initiated (day þ82). After 3 weeks of
voriconazole and 5 weeks of amBisome, ETAs were still yielding
A. fumigatus. Following expert mycologist advice amBisome was
discontinued, and the patient started anidulafungin (day þ93)
whilst continuing voriconazole. We aimed to have voriconazole
levels more than 1 mg/L but less than 6 mg/L and the levels were
regularly monitored. Low trough voriconazole levels of o0.1 mg/L
were found, probably due to the prior exposure to rifampicin, so
we increased the dose from 200 mg b.d. to 300 mg b.d. After this,
voriconazole levels remained around 1.8 mg/L. Mycology experts
advised a minimum of 12 weeks of antifungal therapy. Following
this, a CT chest and head revealed that abscesses and lesions were
decreasing in size. Blood samples were taken and although serum
Aspergillus galactomannan was not detected the β-1,3 glucan level
was 115 pg/mL which was above the 80 pg/mL cut-off for positiv-
ity. Cardiothoracic surgeons reviewed the patient for consideration
of pulmonary abscess excision, but they did not feel intervention
was feasible. A particularly resistant Enterobacter cloacae grew
from chest samples and antibiotics were changed to meropenem
and then ciproﬂoxacin and he ﬁnished 6 weeks of ﬂucloxacillin.
Flucloxacillin was restarted for 2 weeks only a month later (day
þ118), and then again after another 2 weeks as S. aureus grew
from blood cultures, peripherally inserted central catheter (PICC
line) tip and sputum. He remained on anidulafungin and vorico-
nazole and on day þ150 in ICU CT imaging showed chest and
brain lesions were further reducing in size. Anidulafungin was
stopped after 4 months and the patient was switched to oral
voriconazole after 5 months, with a plan to continue this for long-
term maintenance along with ﬂucloxacillin. He was discharged to
the medical high dependency unit (MHDU) after þ166 days on
ICU. He was then transferred to a respiratory ward and made
progress before transfer to a rehabilitation ward and then dis-
charged home. Currently the patient has no chest symptoms or
confusion, can walk with a stick but has some residual weakness.
He remains on ﬂucloxacillin 500 mg b.d and voriconazole
300 mg b.d.
3. Discussion
Aspergillus is a ubiquitous environmental hyaline mould. Typi-
cally, invasive aspergillosis affects patients who are immunocom-
promised such as patients with inherited immunodeﬁciencies,
advanced HIV infection, prolonged neutropenia and allogeneic
hematopoietic stem cell transplantation (HSCT) [5]. Aspergillosis
is also an emerging opportunistic infection in critically ill patients
in the ICU, particularly in patients with COPD or severe liver
disease [6]. Over the last three decades the use of ECMO for the
management of life threatening pulmonary or cardiac failure (or
both) has increased. Prolonged ECMO use has been identiﬁed as a
risk factor for ECMO-related nosocomial infection [2,7]. Patients
are at risk of nosocomial infection whilst on ECMO as they have
multiple portals of entry [2,8]. Fungi such as Candida have been
identiﬁed as a common cause of infection in this group [4,9].
Fig. 1. CT chest scan showing large intrapulmonary collection posterolaterally in
right upper lobe measuring up to 14.5 cm with multiloculated gas and ﬂuid. There
is collapse consolidation of basal right lower lobe.
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We report a case of putative IPA in a patient following ECMO
treatment. The diagnosis of IPA is generally difﬁcult to make in
critically ill patients. There is revised guidance on categorising IPA
written by the European Organization for Research and Treatment
of Cancer/Mycosis Study Group (EORTC/MSG) in which a proven
diagnosis needs histopathologic evidence of fungal invasion
[10,11]. This is meant as guidance on the security of different
diagnostic procedures in determining the likelihood of disease
rather than a diagnostic guideline. In ICU patients, diagnosing IPA
from histological specimens is difﬁcult for many reasons. It is
common for open lung biopsy to be contraindicated due to
coagulation disorders or severe respiratory failure as in our case.
Additionally, radiological ﬁndings in ventilated patients can be
non-speciﬁc and galactomannan antigen detection on serum may
not be useful in patients who are not neutropenic. An alternative
clinical algorithm has been developed for the diagnosis of putative
invasive pulmonary aspergillosis in ICU patients [11]. In our
patient, the negative galactomannan test did not preclude the
diagnosis of pulmonary infection. A galactomannan antigen test
carried out on the CT guided BAL ﬂuid may well have had greater
diagnostic value. Once the brain lesions had been discovered it
may have been diagnostically useful to perform galactomannan,
beta-glucan and PCR tests on CSF samples, however in this case it
would not have altered the management as disseminated asper-
gillosis was already considered the most likely cause. In our
patient the positive b-1,3 glucan was indicative of invasive fungal
infection but due to its almost pan-fungal detection was not able
to determine the pathogen. Moreover, there have been reports
of false positive reactions in patients receiving amoxicillin-
clavulanate or piperacillin–tazobactam, both of which had been
used in this patient, and also cross-reactions in gram negative
bacteraemia.
The ﬁrst case report of invasive aspergillosis in a patient on
ECMO was described in an infant in 2012 [6]. It was diagnosed on
autopsy, which showed ﬂuid ﬁlled lungs, necrosis and angioinva-
sive septated hypha with dichotomous branching most likely to be
due to an Aspergillus species. The authors also carried out a
retrospective analysis of the Extracorporeal Life Support Organiza-
tion (ELSO) registry data looking at the outcomes of 46 adult and
paediatric cases of Aspergillus infection and colonisation. They
found that Aspergillus infection/colonisation was associated with a
70% overall mortality in patients receiving ECMO and that it often
occurred in hosts who did not have known immunodeﬁciencies.
They did not distinguish between infection and colonisation in
these patients or describe how they made the diagnosis. An
Australian series from 2005 to 2011 reported their experience of
treating these patients. They described ECMO patients who had
Aspergillus isolated from clinical specimens, examining their char-
acteristics and outcome [1]. A. fumigatus was the most common
species isolated and many patients did not have ‘classic’ under-
lying risk factors (neutropenia, steroids, immunodeﬁciency, immu-
nosuppressive therapy). The in-hospital mortality rate was found
to be 74%. They used the alternative clinical algorithm that has
been developed for the diagnosis of putative invasive pulmonary
aspergillosis in ICU patients [11]. They identiﬁed two cases of
putative IPA as well as one case of proven IPA. Using the modiﬁed
criteria, we classiﬁed the ﬁrst reported case as a proven IPA and
our case as a putative case as we were unable to take a histology
sample. It is interesting to note that most cases had suffered a
cardiac arrest as did our case (Table 1).
Our patient was managed with combination therapy and
interferon-gamma. Once the brain lesions had been recognised
we were keen to use voriconazole due to its good penetration
into CSF. He made particularly good progress when amphotericin
was switched to anidulafungin whilst he remained on voricona-
zole. This regime is not routinely recommended by IDSA guidance Ta
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[12]. This guidance advises that IPA should be treated with
voriconazole as a ﬁrst line agent, however another agent could
be added or a switch to another drug class could be made in cases
in which salvage therapy is necessary [12]. There is little clinical
data for combination therapy and also conﬂicting results from
studies [13–16] Of note, a recent study has shown that combina-
tion of voriconazole and anidulafungin is synergistic in
voriconazole-susceptible invasive aspergillosis [17]. We added in
interferon-gamma after discussion with immunology experts, as
there is some evidence of impaired production of interferon-
gamma in patients with chronic pulmonary aspergillosis. Again
there is little data on the beneﬁts of its use apart from case reports
of successful treatment in transplant patients not responding to
antifungal therapy [18,19]. This includes two patients with cere-
bral fungal infection (mortality 90%), who both made a full
recovery. Current guidelines on the treatment of aspergillosis
written by the Infectious Diseases Society of America also refer
to its role as an adjunctive anti-fungal therapy for invasive
infection in immunocompromised non-neutropenic patients, par-
ticularly those with chronic granulomatous disease [12]. We felt
our patient would also beneﬁt from long-term voriconazole
treatment. There is limited data on the beneﬁts of long-term
treatment with antifungals but after discussion with expert
mycologists treatment with voriconazole was continued. Recently
a study examining long-term antifungal treatment over a period of
12 months demonstrated an improvement in the health status of
patients and prevention of chronic pulmonary aspergillosis pro-
gression in some patients [20].
Patients undergoing ECMO are at increased risk of infections
compared to other patients in ICU (3). Clinicians should consider
infection with fungus in patients not responding to antibiotics.
From our literature review, we found that ECMO patients with IPA
did not always have ‘classic’ underlying risk factors. We also found
that most cases had suffered a cardiac arrest. Diagnosing IPA in ICU
patients can be difﬁcult but a clinical algorithm to diagnose IPA in
these patients can be useful. Thought should be given to using
combination antifungal therapy and/or interferon-gamma on an
individual patient basis in certain IPA cases. Clinicians should also
monitor voriconazole levels in the blood to guide dosing, and be
aware of antifungal drug interactions and side-effects. In our case
the concomitant use of rifampicin may well have contributed to
initially low voriconazole levels as it is well recognised that this
agent is an inducer of cytochrome P450 (CYP450) leading to more
rapid metabolism of voriconazole. Repeat imaging and sampling
can be useful to assess response to antifungals. Long-term anti-
fungal treatment may need to be considered after discharge from
the ICU.
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